Prevention and treatment of cancer-related infections

Brahm H. Segal, Alison G. Freifeld, Lindsey Robert Baden, Arthur E. Brown, Corey Casper, Erik Dubberke, Michael Gelfand, John N. Greene, Michael G. Ison, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Guido Marcucci, Jose G. Montoya, Ashley Morris Engemann, Ken Rolston, Angelina S. The

Research output: Contribution to journalReview article

102 Citations (Scopus)

Abstract

Previous NCCN guidelines related to infectious complications of cancer were primarily focused on fever and neutropenia. However, the guidelines were revised in 2007 to address prevention and treatment of infections in neutropenic and non-neutropenic immunocompromised patients with cancer. These NCCN guidelines on "Prevention and Treatment of Cancer-Related Infections" replace the previous guidelines on "Fever and Neutropenia." Substantial progress has been made in preventing and treating infectious complications of neutropenia and immunosuppressive therapy in patients with cancer. It is essential to know the patient's quantitative and qualitative immune defects and to stratify the risk for specific pathogens in the context of the history, physical examination, radiologic, and laboratory data. The development of antipseudomonal β-lactam agents and the routine use of empiric antibacterial therapy at the onset of neutropenic fever reduced mortality from bacterial infections.302 More patients were treated with potent cytotoxic regimens (e.g., for acute leukemia) and received allogeneic stem cell transplants; opportunistic viral and fungal infections became an important cause of mortality in these patients. In addition, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis, but rather should continue to incorporate standard infection control measures and demand careful hand-washing by all health care professionals who come into contact with immunocompromised patients.

Original languageEnglish (US)
Pages (from-to)122-174
Number of pages53
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue number2
StatePublished - Mar 11 2008

Fingerprint

Second Primary Neoplasms
Neutropenia
Guidelines
Fever
Immunocompromised Host
Infection Control
Infection
Lactams
Hand Disinfection
Neoplasms
Mortality
Mycoses
Opportunistic Infections
Virus Diseases
Therapeutics
Immunosuppressive Agents
Physical Examination
Leukemia
Stem Cells
History

Keywords

  • Absolute neutrophil count
  • Antibiotic-resistant organisms
  • Antifungal agents
  • Antimicrobial
  • Antiviral agents
  • Cancer therapy
  • Fever
  • Guidelines
  • Infection
  • NCCN Clinical Practice Guidelines
  • Neutropenia
  • Stem cell transplant

ASJC Scopus subject areas

  • Oncology

Cite this

Segal, B. H., Freifeld, A. G., Baden, L. R., Brown, A. E., Casper, C., Dubberke, E., ... The, A. S. (2008). Prevention and treatment of cancer-related infections. JNCCN Journal of the National Comprehensive Cancer Network, 6(2), 122-174.

Prevention and treatment of cancer-related infections. / Segal, Brahm H.; Freifeld, Alison G.; Baden, Lindsey Robert; Brown, Arthur E.; Casper, Corey; Dubberke, Erik; Gelfand, Michael; Greene, John N.; Ison, Michael G.; Ito, James I.; Karp, Judith E.; Kaul, Daniel R.; King, Earl; Mackler, Emily; Marcucci, Guido; Montoya, Jose G.; Engemann, Ashley Morris; Rolston, Ken; The, Angelina S.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. 2, 11.03.2008, p. 122-174.

Research output: Contribution to journalReview article

Segal, BH, Freifeld, AG, Baden, LR, Brown, AE, Casper, C, Dubberke, E, Gelfand, M, Greene, JN, Ison, MG, Ito, JI, Karp, JE, Kaul, DR, King, E, Mackler, E, Marcucci, G, Montoya, JG, Engemann, AM, Rolston, K & The, AS 2008, 'Prevention and treatment of cancer-related infections', JNCCN Journal of the National Comprehensive Cancer Network, vol. 6, no. 2, pp. 122-174.
Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E et al. Prevention and treatment of cancer-related infections. JNCCN Journal of the National Comprehensive Cancer Network. 2008 Mar 11;6(2):122-174.
Segal, Brahm H. ; Freifeld, Alison G. ; Baden, Lindsey Robert ; Brown, Arthur E. ; Casper, Corey ; Dubberke, Erik ; Gelfand, Michael ; Greene, John N. ; Ison, Michael G. ; Ito, James I. ; Karp, Judith E. ; Kaul, Daniel R. ; King, Earl ; Mackler, Emily ; Marcucci, Guido ; Montoya, Jose G. ; Engemann, Ashley Morris ; Rolston, Ken ; The, Angelina S. / Prevention and treatment of cancer-related infections. In: JNCCN Journal of the National Comprehensive Cancer Network. 2008 ; Vol. 6, No. 2. pp. 122-174.
@article{6ecf10c5b6f44c2e80b7e720f41e99ef,
title = "Prevention and treatment of cancer-related infections",
abstract = "Previous NCCN guidelines related to infectious complications of cancer were primarily focused on fever and neutropenia. However, the guidelines were revised in 2007 to address prevention and treatment of infections in neutropenic and non-neutropenic immunocompromised patients with cancer. These NCCN guidelines on {"}Prevention and Treatment of Cancer-Related Infections{"} replace the previous guidelines on {"}Fever and Neutropenia.{"} Substantial progress has been made in preventing and treating infectious complications of neutropenia and immunosuppressive therapy in patients with cancer. It is essential to know the patient's quantitative and qualitative immune defects and to stratify the risk for specific pathogens in the context of the history, physical examination, radiologic, and laboratory data. The development of antipseudomonal β-lactam agents and the routine use of empiric antibacterial therapy at the onset of neutropenic fever reduced mortality from bacterial infections.302 More patients were treated with potent cytotoxic regimens (e.g., for acute leukemia) and received allogeneic stem cell transplants; opportunistic viral and fungal infections became an important cause of mortality in these patients. In addition, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis, but rather should continue to incorporate standard infection control measures and demand careful hand-washing by all health care professionals who come into contact with immunocompromised patients.",
keywords = "Absolute neutrophil count, Antibiotic-resistant organisms, Antifungal agents, Antimicrobial, Antiviral agents, Cancer therapy, Fever, Guidelines, Infection, NCCN Clinical Practice Guidelines, Neutropenia, Stem cell transplant",
author = "Segal, {Brahm H.} and Freifeld, {Alison G.} and Baden, {Lindsey Robert} and Brown, {Arthur E.} and Corey Casper and Erik Dubberke and Michael Gelfand and Greene, {John N.} and Ison, {Michael G.} and Ito, {James I.} and Karp, {Judith E.} and Kaul, {Daniel R.} and Earl King and Emily Mackler and Guido Marcucci and Montoya, {Jose G.} and Engemann, {Ashley Morris} and Ken Rolston and The, {Angelina S.}",
year = "2008",
month = "3",
day = "11",
language = "English (US)",
volume = "6",
pages = "122--174",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",

}

TY - JOUR

T1 - Prevention and treatment of cancer-related infections

AU - Segal, Brahm H.

AU - Freifeld, Alison G.

AU - Baden, Lindsey Robert

AU - Brown, Arthur E.

AU - Casper, Corey

AU - Dubberke, Erik

AU - Gelfand, Michael

AU - Greene, John N.

AU - Ison, Michael G.

AU - Ito, James I.

AU - Karp, Judith E.

AU - Kaul, Daniel R.

AU - King, Earl

AU - Mackler, Emily

AU - Marcucci, Guido

AU - Montoya, Jose G.

AU - Engemann, Ashley Morris

AU - Rolston, Ken

AU - The, Angelina S.

PY - 2008/3/11

Y1 - 2008/3/11

N2 - Previous NCCN guidelines related to infectious complications of cancer were primarily focused on fever and neutropenia. However, the guidelines were revised in 2007 to address prevention and treatment of infections in neutropenic and non-neutropenic immunocompromised patients with cancer. These NCCN guidelines on "Prevention and Treatment of Cancer-Related Infections" replace the previous guidelines on "Fever and Neutropenia." Substantial progress has been made in preventing and treating infectious complications of neutropenia and immunosuppressive therapy in patients with cancer. It is essential to know the patient's quantitative and qualitative immune defects and to stratify the risk for specific pathogens in the context of the history, physical examination, radiologic, and laboratory data. The development of antipseudomonal β-lactam agents and the routine use of empiric antibacterial therapy at the onset of neutropenic fever reduced mortality from bacterial infections.302 More patients were treated with potent cytotoxic regimens (e.g., for acute leukemia) and received allogeneic stem cell transplants; opportunistic viral and fungal infections became an important cause of mortality in these patients. In addition, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis, but rather should continue to incorporate standard infection control measures and demand careful hand-washing by all health care professionals who come into contact with immunocompromised patients.

AB - Previous NCCN guidelines related to infectious complications of cancer were primarily focused on fever and neutropenia. However, the guidelines were revised in 2007 to address prevention and treatment of infections in neutropenic and non-neutropenic immunocompromised patients with cancer. These NCCN guidelines on "Prevention and Treatment of Cancer-Related Infections" replace the previous guidelines on "Fever and Neutropenia." Substantial progress has been made in preventing and treating infectious complications of neutropenia and immunosuppressive therapy in patients with cancer. It is essential to know the patient's quantitative and qualitative immune defects and to stratify the risk for specific pathogens in the context of the history, physical examination, radiologic, and laboratory data. The development of antipseudomonal β-lactam agents and the routine use of empiric antibacterial therapy at the onset of neutropenic fever reduced mortality from bacterial infections.302 More patients were treated with potent cytotoxic regimens (e.g., for acute leukemia) and received allogeneic stem cell transplants; opportunistic viral and fungal infections became an important cause of mortality in these patients. In addition, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis, but rather should continue to incorporate standard infection control measures and demand careful hand-washing by all health care professionals who come into contact with immunocompromised patients.

KW - Absolute neutrophil count

KW - Antibiotic-resistant organisms

KW - Antifungal agents

KW - Antimicrobial

KW - Antiviral agents

KW - Cancer therapy

KW - Fever

KW - Guidelines

KW - Infection

KW - NCCN Clinical Practice Guidelines

KW - Neutropenia

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=40349096506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40349096506&partnerID=8YFLogxK

M3 - Review article

C2 - 18319048

AN - SCOPUS:40349096506

VL - 6

SP - 122

EP - 174

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 2

ER -